

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Guidance development**

**STA Midostaurin for treating advanced systemic  
mastocytosis**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

**Consultation**

- |   |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

<p>A stakeholder stated there was inequality for people with rare diseases because there is less evidence, and inequality in treatments appraised via the single technology appraisal process compared with the highly specialised technologies process. Another stakeholder stated that people who live in regions less well served by knowledgeable consultants may be at a disadvantage if midostaurin is not recommended.</p>
---

<p>The appraisal committee understood that midostaurin was being considered using the single technology appraisal process. The issue of variation in clinician knowledge is a service delivery issue and did not relate to a protected characteristic as defined by the Equality Act 2010. Therefore, these were not considered to be equality issues.</p>
--

- |  |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

No.
-----

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?
No.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
Not applicable

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?
No.

**Approved by Associate Director (name):** ...Linda Landells.....

**Date:** 28 October 2020

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of midostaurin for treating advanced systemic mastocytosis [ID1573]

Issue date: August 2021

## Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No additional potential equality issues been raised during the consultation,

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Not applicable.

**Approved by Associate Director (name):** ...Linda Landells.....

**Date:** 28 July 2021